Sarepta Therapeutics announced on Thursday, December 11, 2025 that it has entered into exchange agreements to refinance roughly $291.4 million of its 1.25% convertible senior notes due 2027. The transaction will replace the existing notes with new senior notes that carry a 1.25% coupon and mature in 2027, providing the company with a more favorable debt structure and extended maturity. The refinancing is expected to reduce the company’s interest expense and improve its balance‑sheet liquidity, supporting ongoing investment in its siRNA pipeline and other strategic initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.